Search research articles
Contact Us
Filters
Showing results (1-10 of 51) with videos related to
Page
of 6
Sort By:
Scandinavian Journal of Clinical and Laboratory Investigation
|
April 14, 2016
Myocardial dysfunction and cardiovascular disease in type 2 diabetes
Anne Pernille Ofstad
Heart Failure Reviews
|
March 9, 2018
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, et al.
Heart Failure Reviews
|
July 4, 2018
Response to the editor
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, et al.
Heart Failure Reviews
|
July 26, 2018
Author's response to: letter to the editor
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, et al.
Cardiovascular Diabetology
|
October 14, 2020
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
Antonio Ceriello, Anne Pernille Ofstad, Isabella Zwiener, et al.
BMC Cardiovascular Disorders
|
November 18, 2015
Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes--a cross-sectional study
Geir Reinvik Ulimoen, Anne Pernille Ofstad, Knut Endresen, et al.
Plos One
|
April 16, 2024
The influence of diagnostic subgroups, patient- and hospital characteristics for the validity of cardiovascular diagnoses-Data from a Norwegian hospital trust
Cathrine Sæthern Rye, Anne Pernille Ofstad, Bjørn Olav Åsvold, et al.
Journal of the American College of Cardiology
|
March 20, 2019
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes
Subodh Verma, Christoph Wanner, Isabella Zwiener, et al.
Journal of Diabetes and Its Complications
|
October 18, 2023
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk
Robert Weingold, Bernard Zinman, Michaela Mattheus, et al.
Diabetes, Obesity & Metabolism
|
January 26, 2023
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes
Moahad S Dar, Christoph Wanner, Nikolaus Marx, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 51) with videos related to
Sort By:
Page
of 6
Scandinavian Journal of Clinical and Laboratory Investigation
|
April 14, 2016
Myocardial dysfunction and cardiovascular disease in type 2 diabetes
Anne Pernille Ofstad
Heart Failure Reviews
|
March 9, 2018
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, et al.
Heart Failure Reviews
|
July 4, 2018
Response to the editor
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, et al.
Heart Failure Reviews
|
July 26, 2018
Author's response to: letter to the editor
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, et al.
Cardiovascular Diabetology
|
October 14, 2020
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
Antonio Ceriello, Anne Pernille Ofstad, Isabella Zwiener, et al.
BMC Cardiovascular Disorders
|
November 18, 2015
Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes--a cross-sectional study
Geir Reinvik Ulimoen, Anne Pernille Ofstad, Knut Endresen, et al.
Plos One
|
April 16, 2024
The influence of diagnostic subgroups, patient- and hospital characteristics for the validity of cardiovascular diagnoses-Data from a Norwegian hospital trust
Cathrine Sæthern Rye, Anne Pernille Ofstad, Bjørn Olav Åsvold, et al.
Journal of the American College of Cardiology
|
March 20, 2019
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes
Subodh Verma, Christoph Wanner, Isabella Zwiener, et al.
Journal of Diabetes and Its Complications
|
October 18, 2023
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk
Robert Weingold, Bernard Zinman, Michaela Mattheus, et al.
Diabetes, Obesity & Metabolism
|
January 26, 2023
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes
Moahad S Dar, Christoph Wanner, Nikolaus Marx, et al.
Page
of 6